Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2014

Is Apixaban Effective for the Prevention of Stroke in
Patients With Non-Valvular Atrial Fibrillation?
Amira Moore
Philadelphia College of Osteopathic Medicine, amiramo@pcom.edu

Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Cardiovascular Diseases Commons, and the Nervous System Diseases Commons
Recommended Citation
Moore, Amira, "Is Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?" (2014). PCOM
Physician Assistant Studies Student Scholarship. 181.
http://digitalcommons.pcom.edu/pa_systematic_reviews/181

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Is apixaban effective for the prevention of stroke in patients with
non-valvular atrial fibrillation?

Amira Moore, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant
Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania
December 20, 2013

ABSTRACT
OBJECTIVE: The objective of this EBM review is to determine whether or not Apixaban is effective
for the prevention of stroke in patients with non-valvular atrial fibrillation.
STUDY DESIGN: Review of three English language primary studies published all published in 2011.
DATA SOUCRES: Three double-blind randomized control trials found using the Cochrane Database
and PubMed.
OUTCOME(S) MEASURED: Outcomes measured were occurrence of stroke (TIA or CVA), systemic
embolism, major bleeding or clinically relevant non-major bleeding, and incidence of death.
RESULTS: Apixaban 2.5mg and 5mg were both superior to Warfarin in the prevention of stroke or
systolic embolism and also decreased the rate of intracranial hemorrhage or other clinically relevant
bleeding. Apixaban 5mg was also demonstrated superiority compared to aspirin 81-324mg in reduction
of stroke, systemic embolism, and death rates.
CONCLUSION: In patients with atrial fibrillation, apixaban was superior to both warfarin (adjusted to
an INR 2.0-3.0) and aspirin (81-324mg) in the indication of prevention of stroke or systemic embolism.
KEY WORDS: Apixaban, atrial fibrillation, stroke, prevention
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INTRODUCTION
Atrial fibrillation is the most common chronic arrhythmia with an incidence and prevalence that
increases with age. Atrial fibrillation can occur in conjunction with other diseases that affect the
function of the heart such as rheumatic heart disease, many forms of valvular heart disease, dilated
cardiomyopathy, atrial septal defect, coronary heart disease and can also present in patients without any
prior history of cardiac disease 5. The mechanism of cause is still debatable. Current theories involve
complex interaction between the initiation and the musculature in the atria that responds to this
impulse.
Symptoms of atrial fibrillation include: irregular heartbeat, tachycardia, lightheartedness,
extreme fatigue, shortness of breath with chest pain. This condition is routinely diagnosed by ECG
interpretation due to its disorganized atrial activity and irregular ventricular response. Episodes of
atrial fibrillation can be classified as paroxysmal (hours to days), persistent (lasts for days and is
corrected with intervention), or permanent 5. Atrial fibrillation reduces the amount of blood that is
pumped from the atria into the ventricles increasing the chance dangerous clot formation which can go
on to embolize and cause infarction. Due to the potential for emboli to reach the brain atrial fibrillation
is known to be the cause of 15-20% of ischemic strokes 5. The focus of this study will be patients that
have non-valvular atrial fibrillation, defined as being in of rheumatic heart disease, a prosthetic heart
valve or previous valve repair.
Atrial fibrillation, in general, is relatively common with an estimated 2.66 million people
having been diagnosed with this disorder in 2010. The average age of a patient with atrial fibrillation is
67 for men and 75 for women 4. Demographics wise atrial fibrillation is also more prevalent in white
than black populations. Occurring to the CDC the estimated cost of treatment for atrial fibrillation was
$6.65 billion per year; this figure includes cost of hospitalization, in/outpatient physician care and
medications 4. Though there is not an exact estimate of how many healthcare visits are due to atrial
fibrillation complications it is projected that 12 million people will have this condition by 2050. In
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addition the mortality rate from atrial fibrillation either as a primary or an underlying cause of death
has been increasing for more than two decades 4.
There are multiple methods in which non-valvular atrial fibrillation is treated. Treatment is
initiated through the use of medication to control rate and rhythm (amiodarone, verapamil, diltiazem)
and surgical ablation therapy. The gold standard anticoagulant prophylaxis for emboli from potential
clot formation is warfarin, but other anticoagulant therapeutic agents such as IV heparin and oral
aspirin have also been successful in the prevention of stroke and other thromboembolic events 5.
Warfarin is recommended for patients with a INRs (international normalized ratio) in between 2.0-3.0
with increased risk for stroke/thromboembolic events. These risks include previous stroke, TIA,
systemic emboli, previous symptomatic heart failure or left ventricular ejection <40%, diabetes, and/or
hypertension3..
Factor Xa inhibitors are another classification of anticoagulants which directly target the
clotting factor Xa to prevent clot formation. Traditionally these agents have been used in place of
warfarin or LMWH to prevent venous thrombosis after hip or knee replacement surgery. Unlike
warfarin these agents have no required need for coagulation monitoring. In 2012 Apixaban, a factor Xa
inhibitor was approved for the prevention of stroke in patients with non-valvular atrial fibrillation after
exploration of the medications efficacy with studies of this patient population.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is apixaban
effective for the prevention of stroke in patients with non-valvular atrial fibrillation”.

METHODS
The studies in this selective Evidence Based Medicine review included men and women
diagnosed with atrial fibrillation. The inclusion criteria were based on the following risk factors: ages
greater than or equal to 75yrs, history of previous stroke (TIA or cerebral infraction), history systemic
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embolism, CHF (left ventricular ejections fraction of less than or equal to 40%), hypertension requiring
pharmacological treatment, or a diagnosis of diabetes mellitus. Exclusion criteria included atrial
fibrillation due to a reversible cause, moderate or severe mitral stenosis, stroke within the previous
seven days, severe renal insufficiency (serum creatinine level of >2.5mg or CrCl of <25ml/min) 1,2,3.
The intervention addressed was Apixaban 2.5mg or 5mg BID compared against Warfarin titrated to an
INR level between 2.0-3.0 and aspirin dosed 81-324mg given once a daily. Outcomes were measured in
the occurrence of stroke and/or systemic embolism, MI, major bleeding, clinically relevant non-major
(CRNM) bleeding or death. These three studies compared are double-blind randomized controlled trials
using apixaban, compared with warfarin, aspirin or both. In all three of the studies detailed in this
review CHADS2 scale was used to measure a patients risk of stroke.
Data sources included both Cochrane and Pubmed databases using the keywords “Atrial
fibrillation”, “apixaban”, “stroke”, “warfarin”, and “prevention” between 2003-2013. All articles were
published in English in 2011 and were selected based on relevance to patients with atrial fibrillation.
Statistics include p-value, RRR, ARR and NNT. Articles were selected based on their relevance to my
clinical question and if they included POEMs.
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Table 1: Demographics & Characteristics of included studies
Study
Type
#pts
Age Inclusion Criteria
Exclusion
W/D
Interventions
(yrs)
Criteria
Men or women aged 50 years
or older with documented
atrial fibrillation that have one
or more of the following risk
factors for stroke:
-Age greater than or equal to
75yrs
Previous stroke, TIA or
systemic embolism
-CHF (left ventricular ejection
fraction of less than or equal to
35%)
-Documented peripheral artery
disease
-HTN requiring
pharmacologic treatment
-DM
-Could not be receiving
vitamin K antagonist therapy
because it was previously
proven to be unsuitable for
them or it was expected to be
unsuitable

Presence of conditions
other than atrial
fibrillation for which the
patient required longterm anticoagulation,
Valvular disease
requiring surgery
Serious bleeding event in
the previous 6 months or
a high risk of bleeding
( active peptic ulcer
disease, platelet count
under 100,000,
hemoglobin level of
<10g/dl, stroke within
the past 10 days,
documented hemorrhagic
tendenices, or blood
dyscrasias)
Current alcohol or drug
abuse/psychosocial
issues

None (early
termination
of the
study)

Apixaban 5mg
1 tab PO BID

20 or
older

Men or women with
documented atrial fibrillation
that have one or more of the
following risk factors for
stroke:
Age greater than or equal to
75yrs
CHF (left ventricular ejection
fraction of less than or equal to
40%)
HTN requiring medication
DM
History of cerebral infraction
or TIA

Recent cerebral
infraction (including
TIA)
Valvular heart disease
Sick sinus syndrome or
severe conduction
disturbance
Non-cardiogenic stroke
requiring aspirin or
aspirin and anti-platelet
agents
Contraindications for
warfarin use
Severe or refractory HTN
Current
thrombocytopenia
(platelet count under
100x109 /L or
hemoglobin less than
10g/dl)
Renal dysfunction
(creatinine clearance <
25ml/min)
LFT abnormalities (ALTs
or AFTs greater than or
equal to 2x the upper
limit of normal)

0

Apixaban
2.5mg or 5mg
1tab po BID

50 or
older

Men or women with
documented atrial
fibrillation that have
one or more of the
following risk factors
for stroke:
Age greater than or
equal to 75yrs
Previous stroke, TIA or
systemic embolism
CHF (left ventricular
ejection fraction of less
than or equal to 40%)
HTN requiring
pharmacologic
treatment
DM

Atrial fibrillation due
to a reversible cause
Moderate or severe
mitral stenosis
Conditions other than
atrial fibrillation that
required
anticogulation
Stroke with the
previous 7 days
Need for aspirin at a
dose >165mg qd or
for both aspirin and
clopidogrel
Severe renal
insufficiency (serum
creatinine level of
>2.5mg/dl or
calculated creatinine
clearance of
<25ml/min)

N/A

Apixaban 5mg
1 tab po BID

Joyner et al1
(2011)

Double- 18201 50 or
blind
older
RCT

Ogawa,
Shinohara,
and
Kanmuri2
(2011)

Double- 222
blind
RCT

Granger,
Double- 5599
Alexandar,
blind
McMurray et RCT
al.3 (2011)
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OUTCOMES
All outcomes were measured in relation to the incidence of stroke or other thromboembolic
event during the time that patients were using the treatment medication (apixaban, warfarin, or aspirin).
Favorable outcomes included a decrease in the rate of stroke or systemic embolism, intracranial
bleeding, myocardial infarction or pulmonary embolism. Unfavorable outcomes included an increase in
the rate of death, stroke, systemic embolism, clinically relevant major or non major bleeds, myocardial
infarction, or death.
Stroke was defined as a focal neurologic deficit, originating from a non-traumatic cause, lasting
for at least 24 hours and was categorized as ischemic or hemorrhagic from evaluation of brain imaging
studies (MRI, CT without contract). Those in whom imaging or an autopsy was not performed were
classified as “uncertain” 3. Systemic embolism was defined as an acute vascular occlusion of an
extremity or organ. Major bleeding was defined as an acute, clinically overt, and with 1 or more of the
following: decrease in hemoglobin >2g/dl over a 24hr period; bleeding requiring a transfusion of >2
units of packed red blood cells, or bleeding at the critical site (intracranial, intraspinal, intraocular,
intra-articular), or bleeding that was fatal 2. Clinically relevant non-major bleeding was defined as acute
or subacute, clinically overt, not major that lead to hospital admission or physical guided medical or
surgical treatment 2.
In the study comparing Apixaban and Warfarin in Patients with Atrial Fibrillation apixaban was
administered at a dose of 5mg twice a day or Warfarin titrated to an INR 2.0-3.0. Those participants
that were on previously initiated warfarin therapy were asked to discontinue their medication three
days before randomization. The primary outcome was ischemic or hemorrhagic stroke or systemic
embolism. This trial was designed to test for non-inferiority with a secondary objectives of testing for
superiority.
In the study comparing the Safety and Efficacy of Oral Direct Factor Xa Inhibitor Apixaban in
Japanese Patients with Non-Valvular Atrial Fibrillation apixaban was given in either doses of 2.5mg or
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5mg twice a day or open-label warfarin titrated to an INR of 2.0-3.0 for 12 weeks. The endpoint being
occurrence of major and clinically relevant non-major bleeding.
In the study Apixaban in Patients with Atrial Fibrillation this patient population consisted of
those whom Vitamin K antagonist therapy was unsuitable. Apixaban was dosed at 5mg twice daily and
aspirin was compared to aspirin dosed 81-324mg daily. The primary outcome was occurrence of stroke
or systemic embolism. This trial was designed to test for superiority of apixaban when compared with
aspirin.
RESULTS
In the study Apixaban and Warfarin in Patients with Atrial Fibrillation the rate of the primary
outcome (stroke or systemic embolism) were compared with patients given apixaban 5mg and those
given Warfarin adjusted to an INR of 2.0-3.0. Rates of stroke or systemic embolism in the apixaban
group were decreased when compared to warfarin (Hazard ratio =0.79; 95% CI, 0.66-0.95; P<0.01;).
With a primary outcome event ratio of apixaban and warfarin 1.27% and 1.60% per year, respectively.
Incidence of major bleeding also decreased in the apixaban group compared to the warfarin group
(Hazard ratio =0.69, 95% CI 0.60-0.80, P<0.001). The yearly event rate of major bleeding in the
apixaban and warfarin groups were 2.13% and 3.09%. In addition the net clinical outcomes (stroke,
systemic embolism, major bleeding, or death from any cause) were lower in the apixaban group than
the warfarin group (Hazard ratio = 0.85, 95% CI 0.78-0.92, P<0.001); with event rates 6.13% and
7.20% respectively. When evaluating the treatment effect of apixaban 5mg versus warfarin the RRR
was 20%, ARR was 0.33% and the NNT was 303.
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Table 2: Rates of Primary and Secondary Event Outcomes in Granger et al 2011
Event Rate (%)
Apixaban
Warfarin
(5mg)
(INR 2.0-3.0)
Stroke or systemic
embolism

1.27%

1.60%

Major bleeding

2.13%

3.09%

Net clinical outcomes*

6.13%

7.20%

* stroke, systemic embolism, major bleeding, or death from any cause

In the study Safety and Efficacy of Oral Direct Factor Xa Inhibitor Apixaban in Japanese
Patients with Non-Valvular Atrial Fibrillation the primary clinical endpoint was major and clinically
relevant non-major (CRNM) bleeding, were compared with patients given apixaban 2.5mg or 5mg BID
and the warfarin (adjusted to an INR 2.0-3.0) group. Due to the small number of patients in each group
no formal statistical testing was conducted and P-values were not calculated for this study. Major and
CRNM bleeding events occurred in 1.4% of apixaban 2.5mg BID group (1 out of 72 patients), 1.4% of
apixaban 5mg BID group (1 out of 71 patients) and 5.3% (4 out of 75) in the warfarin group. In both
apixaban groups there was no incidence of stroke, systemic embolism, MI or death from any cause
while in the warfarin group 4.1% (3 patients), had stroke events including: 1 subarachnoid hemorrhage
and 2 ischemic strokes. No deaths occurred in the warfarin group. When evaluating the treatment effect
of apixaban 2.5mg or 5mg versus warfarin the RRR was 73.5%, ARR was 3.9%, NNT was 26.
In the study Apixaban in Patients with Atrial Fibrillation the primary outcome, occurrence of
stroke or systemic embolism, was compared between patients given apixaban 5mg and patients given
aspirin doses in the range of 81mg-324mg. These patients where all determined to be unsuitable for
warfarin treatment and thus aspirin was used in the control group. Rates of stroke or systemic
embolism were decreased in the apixaban group compared to the aspirin group (Hazard ratio 0.45; 95%
CI 0.32-0.62; P<0.001). The yearly event rates of the primary outcomes are significantly increased in
the aspirin group (event rate of 3.7% per year) compared to the apixaban group (event rate of 1.6% per
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year). Incidence of major bleeding was similar between both apixaban and aspirin groups (Hazard ratio
with apixaban 1.13; 95% CI 0.74 to 1.75; P=0.57). The yearly event ratio of major bleeding for the
apixaban group was 1.4% and 1.2% for the aspirin group. In addition the yearly death rate was 3.5%
per year in the apixaban group and 4.4% in the aspirin group. When evaluating the treatment effect of
apixaban 5mg versus aspirin 81-324mg the RRR was 22.7%, ARR was 0.5%, NNT was 200. Due to the
treatment benefit in favor apixaban for the primary outcome which exceeded 4 SD this study was
terminated early. 1. Study termination was recommended after the first confirmatory data analysis.
Table 3: Rates of Primary and Secondary Event Outcomes
Event Rates (%)
Apixaban (5mg)

Aspirin (81mg-324mg)

Stroke or systemic embolism

1.60%

3.70%

Major bleeding

1.40%

1.20%

Deaths (from any cause)

3.50%

4.40%

DISCUSSION
Anticoagulation therapy with warfarin is the gold standard therapy for patients with atrial
fibrillation, but not only apixaban, but rivaroxaban (another Factor XA inhibitor) and dabigatran (an
oral direct thrombin inhibitor) have also been proven to be noninferior or superior to warfarin in
regards to stroke prevention5. A major complication of warfarin is an increased risk of intracranial
bleeding including hemorrhagic stroke. Patients on warfarin are required to their INRs monitored to
track their rate of anticoagulation to prevent aforementioned bleeding. In addition patients using
warfarin must control their diet for foods that are high in vitamin K ( liver, green tea, green leafy
vegetables) which is the antidote to the anticoagulative effects of the medication 5. Apixaban, unlike
warfarin, has no required coagulation monitoring nor does the patient have to alter their diet to prevent
interactions with the medication. A possible limitation of the studies that included warfarin are due to
he studies not being completely blinded. Although randomization occurred blind, those patients on
warfarin were required to have INR monitoring.
Apixaban's original indication was prevention of venous thrombosis after hip and knee surgery
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and was recently approved by the FDA for the of stroke prevention in patients with atrial fibrillation in
Dec 2012. Due to how recent FDA approval was to the time that the research for this study was
conducted statistically reliable cost effective studies for apixaban when compared to warfarin are not
available. The price of apixaban is partially covered by Medicare Part D but the out-of-pocket prices of
the medication vary across insurance providers.
CONCLUSION
Based on the three studies above, it can be concluded that Apixaban is effective in the
prevention of stroke in patients with non-valvular atrial fibrillation. Apixaban doses 2.5and 5mg had
consistently lower rates of stroke, systemic embolism, and bleeding (major or CRNM) when compared
to the groups treated with warfarin 2,3. Apixaban 5mg was proven to have lower rates of stroke or
systemic embolism in patients which Vitamin K antagonist therapy was unsuitable, when compared to
aspirin 81-324mg. In addition patients with atrial fibrillation, apixaban was superior to both warfarin
(adjusted to an INR 2.0-3.0) and aspirin (81-324mg) in the indication of prevention of stroke or
systemic embolism.
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